Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
BioNTech SE
Incyte Corporation
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Amgen
Dana-Farber Cancer Institute
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Fate Therapeutics
National Institutes of Health Clinical Center (CC)
Novartis
University of Chicago
Memorial Sloan Kettering Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Merck Sharp & Dohme LLC
Eli Lilly and Company
SillaJen, Inc.
Eli Lilly and Company
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Vividion Therapeutics, Inc.
HC Biopharma Inc.
Centre Oscar Lambret
M.D. Anderson Cancer Center
University of California, Davis
Pfizer
M.D. Anderson Cancer Center
University of California, Irvine
City of Hope Medical Center
RemeGen Co., Ltd.
Pfizer
BeOne Medicines
Astellas Pharma Inc
M.D. Anderson Cancer Center
Washington University School of Medicine
Regeneron Pharmaceuticals
University of Oklahoma
University of Alabama at Birmingham
University of Colorado, Denver
HC Biopharma Inc.
NRG Oncology
M.D. Anderson Cancer Center
Beijing Wehand-Bio Pharmaceutical Co., Ltd
Dana-Farber Cancer Institute
Abramson Cancer Center at Penn Medicine
University of Utah
Dana-Farber Cancer Institute
National Cancer Institute (NCI)